Weekly Report on the Greater Health Industry: Conovo Bio Files for HKEX Listing; 2.387 Billion Yuan Valuation, Another 'Huadong Medicine Group' Company Goes Public

Connexicon Bio submits listing application to HKEX

On January 25, Conno Biotech submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Guotou Securities International acting as the exclusive sponsor. Conno Biotech focuses on the research, development, production, and commercialization of mitochondrial medicine and health products, studying diseases caused by mitochondrial dysfunction, providing scientific solutions through a "Detection—Intervention—Evaluation—Reintervention" approach. (Source: Sina Finance)

RMB 2.387 billion, "Huadong Medicine System" listed company +1

On January 22, BIOSUN PHARMA officially submitted its prospectus to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the exclusive sponsor. Established in 2020, BIOSUN PHARMA is a pharmaceutical company nearing commercialization, focusing on the development of oral small molecule drugs in the fields of oncology and autoimmune diseases. The company has built a highly selective small molecule drug discovery platform and a molecular glue discovery platform. Its pipeline includes one new drug at the New Drug Application (NDA) stage (Bexetinib), one registrational clinical-stage candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16). (Source: Sina Finance)

Guangzhou AI Medical Assistant "Sui Xiao Yi" Released

To enhance the medical experience for citizens, the Guangzhou Health Commission has launched the AI medical assistant "Sui Xiao Yi," which has officially been integrated into the Ant Fortune App. By downloading the Ant Fortune App, citizens can interact with "Sui Xiao Yi" through voice or text to access a full range of intelligent services including health consultations, smart registration, waiting room call-ups, medical insurance payments, report inquiries, and interpretations. It is reported that currently, several city-level intelligent systems across China, such as Chongqing's "Yu Xiao Jian" and Guangzhou's "Sui Xiao Yi," have been incorporated into the Ant Fortune App, providing users with diverse services like health consultations, appointment scheduling, virtual medical accompaniment, and report interpretation. Additionally, ten regions including Heilongjiang, Xinjiang, and Zhengzhou have adopted the Ant Fortune App as the cooperative signing platform for the "Digital Family Doctor." (Source: Sina Finance)

RMB 10 Million! Beijing Shijitan Hospital Plans to Transfer an AI Laparoscopic Visualization Technology

Beijing Shijitan Hospital, Capital Medical University, Announces Technology Transfer Disclosure: Plans to Transfer Patent for "A Focal Point Tracking AI Endoscopic Visualization Method, System, and Storage Medium" to Industry Partner for RMB 10 Million (Source: Arterial Network)

Neowise Biotechnology Completes Over 200 Million Yuan in Series B Financing

Recently, Neowise Biotechnology, Co., Ltd. (hereinafter referred to as "Neowise Biotechnology" or "the Company"), an innovative enterprise focusing on the development of TCR-T immunocyte therapeutic drugs for solid tumors, announced the completion of a Series B financing round exceeding 200 million yuan. This round of financing was jointly led by Apricot Capital and a well-known industrial fund, with participation from Delian Capital, Oriza Holdings, and Suzhou Angel Mother Fund. Existing shareholders Tonggao Capital and GEM continued their strong support. Heryue Capital served as the exclusive financial advisor for this round of financing. (Source: Arterial Network)

Harvey Medical Completes Pre-A Round Financing Worth Tens of Millions of Yuan

Recently, Shenzhen Havvie Biomedical Technology Co., Ltd. (hereinafter referred to as "Havvie Medical") announced the completion of a multi-million yuan Pre-A round of financing. This round of financing was led by the Starlink Smart Investment Fund under Rushan Capital. The funds will mainly be used to accelerate Havvie Medical's original technological iteration in the field of respiratory support, expand production capacity, and promote global commercialization, especially to drive the deep market layout of portable oxygen generators and ventilators in high-end European and American markets. Powered by the innovative strength of Chinese manufacturing, Havvie Medical is committed to helping the world breathe again. (Source: Arterial Network)

DIS Medical Completes Tens of Millions of A2 Round Financing

Recently, Hangzhou Disi Medical Biotechnology Co., Ltd. completed a multi-million yuan A2 round of financing. This round was led by Fortune Venture Capital, with continued additional investment from Puhua Capital, and WinX Capital serving as the exclusive financial advisor. This comes just half a year after the company’s previous round of financing. The funds will accelerate the promotion of Disi Medical's super-micro surgical robot from technological leadership to market adoption. (Source: Arterial Network)

Neovision Bio completes additional A+ round financing worth tens of millions of yuan

Shenzhen Xinyue Biotechnology Co., Ltd. (hereinafter referred to as "Xinyue Biotech") has recently completed a multi-million yuan Series A+ strategic financing round. This round of financing was led by existing shareholder and Hong Kong Stock Exchange-listed company XtalPi (2228.HK), which made an additional investment. This marks an important capital boost for Xinyue Biotech within half a year following an earlier investment by XtalPi. (Source: Arterial Network)

Nine Departments Including the Ministry of Commerce Release the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry"

On January 22, the Ministry of Commerce and eight other departments issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry" (hereinafter referred to as the "Opinions"). The "Opinions" mentioned guiding the coordinated development of commercial health insurance and basic medical insurance, supporting insurance institutions in developing commercial health insurance products suitable for pharmaceutical retail scenarios to meet the diverse protection needs of the public. It encourages commercial insurance institutions to launch commercial health insurance products that include health management and elderly care services. For high-value drugs and devices, it supports pharmaceutical retail enterprises and commercial insurance institutions in establishing a risk-sharing and efficient payment coordination mechanism to effectively reduce patients' payment pressure. (Source: Beijing Business Today)